4.5 Article

Soft Tissue Sarcoma, Version 2.2016 Clinical Practice Guidelines in Oncology

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0078

关键词

-

类别

资金

  1. Johnson Johnson
  2. ARIAD Pharmaceuticals, Inc.
  3. Bayer HealthCare
  4. Blueprint Medicines
  5. Deciphera Pharmaceuticals, LLC
  6. Novartis Pharmaceuticals Corporation
  7. Pfizer Inc.
  8. Genentech, Inc.
  9. Bristol-Myers Squibb Company
  10. Children's Oncology Group
  11. Astex Pharmaceuticals, Inc.
  12. CytRx Corporation
  13. Eisai Inc.
  14. Morphotek Inc.
  15. Plexxikon Inc.
  16. Threshold Pharmaceuticals
  17. TRACON Pharmaceuticals, Inc.
  18. AB Science
  19. Amgen Inc.
  20. BioMed Valley Discoveries, Inc.
  21. SARC Threshold Pharmaceuticals
  22. Daiichi-Sankyo Co.
  23. ImClone Systems Incorporated
  24. AROG Pharmaceuticals LLC
  25. ArQule, Inc.
  26. Immune Design
  27. Janssen Pharmaceutical Products, LP
  28. Merck Co., Inc.
  29. SARC
  30. Synta Pharmaceuticals Corp.

向作者/读者索取更多资源

Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Guidelines for Soft Tissue Sarcoma (available at NCCN.org) provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as intra-abdominal/retroperitoneal STS, gastrointestinal stromal tumor, desmoid tumors, and rhabdomyosarcoma. This manuscript discusses guiding principles for the diagnosis and staging of STS and evidence for treatment modalities that include surgery, radiation, chemoradiation, chemotherapy, and targeted therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据